<?xml version="1.0" encoding="utf-8" standalone="yes" ?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Pubs on CityU Wang Lab</title>
    <link>/pub/</link>
    <description>Recent content in Pubs on CityU Wang Lab</description>
    <generator>Hugo -- gohugo.io</generator>
    <language>en-us</language>
    <lastBuildDate>Thu, 07 Jun 2018 13:07:31 +0200</lastBuildDate>
    
	<atom:link href="/pub/index.xml" rel="self" type="application/rss+xml" />
    
    
    <item>
      <title>mTORC1 Promotes Metabolic Reprogramming by the Suppression of GSK3-Dependent Foxk1 Phosphorylation.</title>
      <link>/pub/1804mc_wx/</link>
      <pubDate>Thu, 07 Jun 2018 13:07:31 +0200</pubDate>
      
      <guid>/pub/1804mc_wx/</guid>
      <description>Author He L, Gomes AP†, Wang X†, Yoon SO, Lee G, Nagiec M, Cho S, Chavez A, Islam T, Yu Y, Asara JM, Kim BY, Blenis J.
Molecular Cell 2018, doi:https://doi.org/10.1016/j.molcel.2018.04.024
Abstract Highlights
 mTORC1 suppresses GSK3-dependent Foxk1 phosphorylation Foxk1 phosphorylation promotes 14-3-3 binding and nuclear exclusion Foxk1 transcriptionally regulates Hif1α expression Foxk1 and Hif1α contribute to mTORC1-regulated metabolic reprogramming  Summary
The mammalian Target of Rapamycin Complex 1 (mTORC1)-signaling system plays a critical role in the maintenance of cellular homeostasis by sensing and integrating multiple extracellular and intracellular cues.</description>
    </item>
    
    <item>
      <title>Molecular subtyping of colorectal cancer: recent progress, new challenges and emerging opportunities.</title>
      <link>/pub/1802scb_ww/</link>
      <pubDate>Thu, 17 May 2018 13:07:31 +0200</pubDate>
      
      <guid>/pub/1802scb_ww/</guid>
      <description>Author Wang W†, Kandimalla R†, Huang H†, Zhu L, Li Y, Gao F, Goel A*,Wang X*
Seminars in Cancer Biology 2018, doi:10.1016/j.semcancer.2018.05.002
Abstract Colorectal cancer (CRC) is one of the leading causes of cancer-related deaths worldwide. Similar to many other malignancies, CRC is a heterogeneous disease, making it a clinical challenge for optimization of treatment modalities in reducing the morbidity and mortality associated with this disease. A more precise understanding of the biological properties that distinguish patients with colorectal tumors, especially in terms of their clinical features, is a key requirement towards a more robust, targeted-drug design, and implementation of individualized therapies.</description>
    </item>
    
    <item>
      <title>Genome-wide discovery and identification of a novel miRNA signature for recurrence prediction in stage II and III colorectal cancer</title>
      <link>/pub/1803ccr_gao/</link>
      <pubDate>Thu, 01 Mar 2018 13:50:46 +0200</pubDate>
      
      <guid>/pub/1803ccr_gao/</guid>
      <description>Author Kandimalla R†, Gao F†, Matsuyama T, Ishikawa T, Uetake H, Takahashi N, Yamada Y, Becerra C, Kopetz S, Wang X* and Goel A*.
Clin Cancer Res 2018 Purpose The current TNM (Tumor Node Metastasis) staging system is inadequate at identifying high-risk colorectal cancer (CRC) patients. Using a systematic and comprehensive-biomarker discovery and validation approach, we aimed to identify a miRNA-recurrence classifier (MRC) that can improve upon the current TNM-staging as well as superior to currently offered molecular assays.</description>
    </item>
    
    <item>
      <title>The RNA binding protein SORBS2 suppresses metastatic colonization of ovarian cancer by stabilizing tumor-suppressive immunomodulatory transcripts.</title>
      <link>/pub/1801gb_ww/</link>
      <pubDate>Mon, 22 Jan 2018 13:07:31 +0200</pubDate>
      
      <guid>/pub/1801gb_ww/</guid>
      <description>Author Zhao L†, Wang W†, Huang S†, Yang Z†, Xu L†, Yang Q†, Zhou X, Wang J, Shen Q, Wang C, Le X, Feng M, Zhou N, Lau WB, Lau B, Yao S, Yi T, Wang X, Zhao X, Wei Y and Zhou S.
Genome Biology 2018, doi:https://doi.org/10.1186/s13059-018-1412-6
Abstract Background Ovarian cancer constitutes one of the most lethal gynecologic malignancies for females. Currently, early detection strategies and therapeutic options for ovarian cancer are far from satisfactory, leading to high diagnosis rates at late stages and disease relapses.</description>
    </item>
    
    <item>
      <title>A MicroRNA Signature Associated With Metastasis of T1 Colorectal Cancers to Lymph Nodes.</title>
      <link>/pub/1702gas_gao/</link>
      <pubDate>Thu, 30 Nov 2017 13:50:46 +0200</pubDate>
      
      <guid>/pub/1702gas_gao/</guid>
      <description>Author Ozawa T†, Kandimalla R†, Gao F†, Nozawa H, Hata K, Nagata H, Okada S, Izumi D, Baba H, Fleshman J, Wang X*, Watanabe T, Goel A.
Gastroenterology 2017 Abstract Most T1 colorectal cancers treated by radical surgery can now be cured by endoscopic submucosal dissection. Although 70%-80% of T1 colorectal cancers are classified as high risk, &amp;lt;16% of these patients actually have lymph node metastases. Biomarkers are needed to identify patients with T1 cancers with the highest risk of metastasis, to prevent unnecessary radical surgery.</description>
    </item>
    
    <item>
      <title>Consensus molecular subtypes of colorectal cancer are recapitulated in in vitro and in vivo models.</title>
      <link>/pub/1800cd_wx/</link>
      <pubDate>Mon, 09 Oct 2017 13:07:31 +0200</pubDate>
      
      <guid>/pub/1800cd_wx/</guid>
      <description>Author Linnekamp JF†, van Hooff SR†, Prasetyanti PR, Kandimalla R, Buikhuisen JY, Fessler E, Ramesh P, Lee KAST, van Bochove GGW, de Jong JH, Cameron K, van Leersum R, Rodermond HM, Franitza M, Nürnberg P, Mangiapane LR, Wang X, Clevers H, Vermeulen L, Stassi G and Medema JP.
Cell Death and Differentiation 2018, doi:10.1038/s41418-017-0011-5
Abstract Colorectal cancer (CRC) is a highly heterogeneous disease both from a molecular and clinical perspective.</description>
    </item>
    
    <item>
      <title>Genome-wide Discovery of a Novel Gene-expression Signature for the Identification of Lymph Node Metastasis in Esophageal Squamous Cell Carcinoma.</title>
      <link>/pub/1703ann_gao/</link>
      <pubDate>Sun, 10 Sep 2017 13:07:31 +0200</pubDate>
      
      <guid>/pub/1703ann_gao/</guid>
      <description>Author Fuminori Sonohara; Feng Gao; Naoki Iwata; Mitsuro Kanda; Masahiko Koike; Naoki Takahashi; Yasuhide Yamada; Yasuhiro Kodera; Xin Wang; Ajay Goel
Annals of Surgery 2017, doi:10.1097/SLA.0000000000002622
Objective This study aimed to develop a gene-expression signature for identification of lymph node (LN) metastasis in esophageal squamous cell carcinoma (ESCC) patients.
Summary of Background Data LN metastasis is recognized as the most important independent risk factor for therapeutic decision-making of ESCC patients.</description>
    </item>
    
    <item>
      <title>A multidimensional network approach reveals microRNAs as determinants of the mesenchymal colorectal cancer subtype.</title>
      <link>/pub/1604onco_wx/</link>
      <pubDate>Thu, 17 Nov 2016 13:07:31 +0200</pubDate>
      
      <guid>/pub/1604onco_wx/</guid>
      <description>Author Fessler E, Jansen M, De Sousa E Melo F, Zhao L, Prasetyanti PR, Rodermond H, Kandimalla R, Linnekamp JF, Franitza M, van Hooff SR, de Jong JH, Oppeneer SC, van Noesel CJM, Dekker E, Stassi G, Wang X*, Medema JP*, and Vermeulen L*.
Cell Death and Differentiation 2018, doi:10.1038/onc.2016.134
Abstract Colorectal cancer (CRC) is a heterogeneous disease posing a challenge for accurate classification and treatment of this malignancy. There is no common genetic molecular feature that would allow for the identification of patients at risk for developing recurrences and thus selecting patients who would benefit from more stringent therapies still poses a major clinical challenge.</description>
    </item>
    
    <item>
      <title>The consensus molecular subtypes of colorectal cancer</title>
      <link>/pub/1602nm_wx/</link>
      <pubDate>Sun, 13 Mar 2016 13:07:31 +0200</pubDate>
      
      <guid>/pub/1602nm_wx/</guid>
      <description>Author Guinney J†, Dienstmann R†, Wang X†, de Reyniès A†, Schlicker A†, Soneson C†, Marisa L†, Roepman P†, Nyamundanda G†, Angelino P, Bot BM, Morris JS, Simon IM, Gerster S, Fessler E, De Sousa E Melo F, Missiaglia E, Ramay H, Barras D, Homicsko K, Maru D, Manyam GC, Broom B, Boige V, Perez-Villamil B, Laderas T, Salazar R, Gray JW, Hanahan D, Tabernero J, Bernards R, Friend SH, Laurent-Puig P, Medema JP, Sadanandam A, Wessels L, Delorenzi M, Kopetz S, Vermeulen L &amp;amp; Sabine Tejpar</description>
    </item>
    
    <item>
      <title>Transcription factors LRF and BCL11A independently repress expression of fetal hemoglobin.</title>
      <link>/pub/1603sci_wx/</link>
      <pubDate>Fri, 15 Jan 2016 13:07:31 +0200</pubDate>
      
      <guid>/pub/1603sci_wx/</guid>
      <description>Author Masuda T, Wang X, Maeda M, Canver MC, Sher F, Funnell APW, Fisher C, Suciu M, Martyn GE, Norton LJ, Zhu C, Kurita R, Nakamura Y, Xu J, Higgs DR, Crossley M, Bauer DE, Orkin SH, Kharchenko PV, Maeda T
**Science ** 2016, doi:10.1126/science.aad3312.
Abstract Genes encoding human β-type globin undergo a developmental switch from embryonic to fetal to adult-type expression. Mutations in the adult form cause inherited hemoglobinopathies or globin disorders, including sickle cell disease and thalassemia.</description>
    </item>
    
    <item>
      <title>The oncogenic BRD4-NUT chromatin regulator drives aberrant transcription within large topological domains</title>
      <link>/pub/1601gd_wx/</link>
      <pubDate>Mon, 11 Jan 2016 13:07:31 +0200</pubDate>
      
      <guid>/pub/1601gd_wx/</guid>
      <description>Author Alekseyenko AA†, Walsh EM†, Wang X†, Grayson AR, Hsi PT, Kharchenko PV, Kuroda MI, and French CA
Genes Dev 2015, doi:10.1101/gad.267583.115.
Abstract NUT midline carcinoma (NMC), a subtype of squamous cell cancer, is one of the most aggressive human solid malignancies known. NMC is driven by the creation of a translocation oncoprotein, BRD4-NUT, which blocks differentiation and drives growth of NMC cells. BRD4-NUT forms distinctive nuclear foci in patient tumors, which we found correlate with ∼100 unprecedented, hyperacetylated expanses of chromatin that reach up to 2 Mb in size.</description>
    </item>
    
    <item>
      <title>Selected Publications</title>
      <link>/pub/selected-publications/</link>
      <pubDate>Mon, 10 Aug 2015 13:07:31 +0200</pubDate>
      
      <guid>/pub/selected-publications/</guid>
      <description>Zhao L, Huang S, Mei S, Yang Z, Xu L, Zhou N, Yang Q, Shen Q, Wang W, Le X, Lau WB, Lau B, Wang X, Yi T, Zhao X, Wei Y, Warner M, Gustafsson JA, Zhou S. Pharmacological activation of estrogen receptor beta augments innate immunity to suppress cancer metastasis. PNAS 2018, 115(16):E3673-E3681
 Xu Z, Wang W, Ren Y, Zhang W, Fang P, Huang L, Wang X and Shi P.</description>
    </item>
    
    <item>
      <title>Poor prognosis colon cancer is defined by a distinct molecular subtype and develops from serrated precursor lesions</title>
      <link>/pub/1301nm_wx/</link>
      <pubDate>Sun, 19 May 2013 13:07:31 +0200</pubDate>
      
      <guid>/pub/1301nm_wx/</guid>
      <description>Author De Sousa E Mello, F†, Wang X†, Jansen M, Fessler E, Trinh A, et al
Nature Medicine 2013, doi:10.1038/nm.3174.
Abstract Colon cancer is a clinically diverse disease. This heterogeneity makes it difficult to determine which patients will benefit most from adjuvant therapy and impedes the development of new targeted agents. More insight into the biological diversity of colon cancers, especially in relation to clinical features, is therefore needed. We demonstrate, using an unsupervised classification strategy involving over 1,100 individuals with colon cancer, that three main molecularly distinct subtypes can be recognized.</description>
    </item>
    
  </channel>
</rss>